Navigation Links
Novan Awarded $7.8 Million Contract by BARDA to Develop a Medical Countermeasure for Thermal Burns
Date:8/26/2013

DURHAM, N.C., Aug. 26, 2013 /PRNewswire/ -- Novan Therapeutics announced today that the U.S. Department of Health and Human Services has entered into a contract with Novan to advance the development of a nitric oxide-based therapy as a topical treatment for thermal burns.  The Biomedical Advanced Research and Development Authority (BARDA), an agency within the Office of the Assistant Secretary for Preparedness and Response, awarded this contract.  It is widely believed a mass casualty event caused by natural or intentional threats to public health could result in tens of thousands of burn patients which would overwhelm the burn care infrastructure presently available in hospitals across the United States. 

(Logo: http://photos.prnewswire.com/prnh/20130228/NE68367LOGO )

Under the terms of the contract, BARDA will provide funding of $7.8 million over two years.  The contract will support the pharmaceutical development of the Nitric Oxide Advanced Healing (NOAH) technology including formulation work, nonclinical toxicology, and proof of concept studies in models of deep partial thickness and full thickness thermal injuries.  This project is designed to enable the future clinical investigation of the medical countermeasure.

"We are honored that BARDA selected our team to develop a nitric oxide therapy for thermal burns," said Nathan Stasko, president of Novan.  Nitric oxide, a molecule produced by the human body, has been demonstrated throughout peer-reviewed literature to speed the migration of epidermal cells, stimulate new blood vessel growth, modulate inflammation, and re-model the wound bed.  Dr. Stasko continued, "The link between nitric oxide and the body's ability to heal is well established.  The challenge is to create stable nitric oxide drugs that 'perform on command' and deliver a controlled, sustained dose that will supplement the body's ability to regenerate tissue.  Our platform technology has allowed us to pursue the development of drugs intended to harness the healing power of nitric oxide with results extending far beyond bioterrorism.  We believe the NOAH technology creates a gateway into regenerative medicine and could lead to therapies that can help heal both acute and chronic wounds."

The findings under this contract will complement Novan's existing efforts to develop nitric oxide therapies for combat casualties, multi-drug resistant infections, and chronic wounds outside the scope of this contract.  For example, Novan has evaluated the effects of topical nitric oxide therapies in several porcine wound models.  Clear enhancements in the rate of wound re-epithelialization have been observed.  Dr. Stasko said, "These results and the BARDA-funded NOAH program support the company's strategy to create products for the multi-billion dollar advanced wound care market."

About Novan, Inc.

Novan Inc., based in the Research Triangle Park area of North Carolina, is a clinical-stage drug development company focused on topical delivery of nitric oxide.  Nitric oxide, one of the most studied molecules in human physiology, has been shown to exhibit anti-microbial activity and to promote vasodilation, regulate inflammation, stimulate tissue repair, and even eradicate cancer cells. The company's proprietary platform technology enables the stable storage and release of nitric oxide in a variety of dosage forms.  Novan is currently developing innovative, first-in-class therapies for the field of dermatology and wound care.

For more information, please contact:

Julia Brannan
Pascale Communications
908-464-2470
novan@pascalecommunications.com
www.novantherapeutics.com


'/>"/>
SOURCE Novan Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novan Announces Promising Results of SB204 Clinical Study
2. Novans SB204 Could Be First Topical Sebum Inhibitor
3. Fountain Valley Regional Medical Center Becomes Orange Countys First Hospital Awarded Advanced Certification In Inpatient Diabetes Care
4. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
5. Arisaph Pharmaceuticals Awarded Phase I STTR Grant To Develop Small Molecule Immune Modulators
6. All Time Medical awarded a Google Trusted Store badge.
7. Dynamic Healthcare Services Awarded Two Oxygen Equipment Competitive Bidding Contracts
8. Instrumentation Laboratory Awarded Premier Healthcare Alliance Contract For Hemostasis Product Line
9. Great Lakes NeuroTechnologies Awarded Patent For Technology To Treat Parkinsons Disease With Brain Stimulation During Sleep
10. Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies
11. Tunitas Therapeutics Awarded Phase II SBIR Grant to Advance Asthma Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... 2017  Fortuna Fix Inc. (" Fortuna "), a ... to eliminate the need for embryonic and fetal stem cells ... diseases. Fortuna announced today the launch ... Fehlings , MD, PhD; Father Kevin FitzGerald , S.J., ... Professor James Giordano , PhD. "We are ...
(Date:5/4/2017)... 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global ... solutions, today announced that it is teaming up with ... Limited to lower diabetes healthcare costs in ... which is available throughout all provinces and territories in ... eligible for additional savings when shopping for Dario supplies ...
(Date:5/3/2017)... , May 3, 2017  Kalorama Information notes ... nine percent next year and this is projected ... hematopoietic stem cell (HSCT) or bone marrow transplants ... technologies are well-suited for this task. This according ... publisher Kalorama Information. The various PCR-based methodologies, Sanger ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... 2017 , ... Most us are familiar with the sound of occasional popping ... Osteoarthritis Initiative shows that certain people who experience consistent joint popping, grating and ... doctors the opportunity to treat patients before the problem becomes pronounced, potentially hedging off ...
(Date:5/26/2017)... ... May 26, 2017 , ... Amir Qureshi, MD is the ... versatile, patient-centric spinal cord stimulation system. The Nuvectra™ Algovita SCS System has been FDA ... to be the first in Arkansas to introduce the most powerful SCS system and ...
(Date:5/26/2017)... ... 2017 , ... On May 24, the Congressional Budget Office (CBO) projected that ... May 4, would result in 23 million Americans losing their health insurance by 2026 ... Protection and Affordable Care Act (ACA). , “It is clear from the CBO ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon ... informational blog post on insurance options. If a Bay Area patient has to search ... time and money. Visiting an in-network provider for a second opinion can ensure a ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: the ... others. “Cactus Jack: Against All Odds” is the creation of published author, Walter ... is married to Jack Carlisle’s third child Jane. Walter. Walter and Jane have ...
Breaking Medicine News(10 mins):